<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68898">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016040</url>
  </required_header>
  <id_info>
    <org_study_id>#12-030</org_study_id>
    <nct_id>NCT02016040</nct_id>
  </id_info>
  <brief_title>Focal Therapy Using HIFU for Localised Prostate Cancer</brief_title>
  <official_title>Focal Therapy Using High Intensity Focused Ultrasound (ABLATHERM®) for Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the rate of patients without cancer detected by biopsies performed six months
      after hemi-ablation with high intensity focused ultrasound (HIFU) (Ablatherm ®).

      Evaluate the impact of the HIFU treatment on continence, sexuality and quality of life at
      one year. Evaluate the cost of hemi-ablation HIFU treatment.

      A prospective single -centre phase II, single arm, cohort study (therapeutic confirmatory)
      offering focal therapy using HIFU (Ablatherm ®) to 25 men with histologically proven
      localised low to intermediate risk prostate cancer (PSA ≤10ng/ml, Gleason score ≤ 7 ,T1c or
      T2b ). Precise mapping and characterisation of the disease will be established using
      multi-parametric (mp)-MRI and prostate biopsies. Only the lobe with disease will be treated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of patients without cancer</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MRI,Biopsy,PSA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate tolerance of hemi-ablation</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the hemi-ablation HIFU treatment on continence, sexuality and quality of life</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of hemi-ablation HIFU treatment</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HIFU hemi-ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Focal  Therapy Using  High  Intensity Focused  Ultrasound (Ablatherm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High  Intensity Focused  Ultrasound</intervention_name>
    <arm_group_label>HIFU hemi-ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥ 50 years

          -  Clinical stage T1c (normal digital rectal examination) or T2a (one palpable nodule on
             digital rectal examination)

          -  PSA ≤10 ng / mL

          -  Presence of cancer on biopsies (12 sampling biopsies  plus 2-4 targeted biopsies on
             one side and limited to one or two contiguous areas of prostate: basic and middle or
             middle and apex).

          -  Gleason score ≤ 7 (3+4)

          -  Flowmetry &gt; 12 mL / sec for a voided volume of 125 mL

          -  PVR &lt;100 mL

          -  Patient with normal anal and rectal anatomy.

          -  Patient with a condition corresponding to a classification of ASA 1 or 2.

          -  Patient signing ICF and agreed for following monitoring

        Exclusion Criteria:

          -  Patient with an ASA score 3.

          -  Patient in clinical stage T1a, T1b, T2b, T2c or T3.

          -  Patient with a tumor visible on MRI: Located at a distance less than 5 mm from the
             midline. Located less than 6 mm from the apex real

          -  Metastatic lymph node or metastasis discovered by MRI and bone scan.

          -  Patient previously treated for his prostate cancer by hormone therapy.

          -  Patient with a distance between the rectal mucosa and prostate capsule over 8 mm
             thick

          -  History of inflammatory bowel disease

          -  Rectal fistula.

          -  History of pelvic radiotherapy.

          -  History of bladder cancer.

          -  History of bladder neck sclerosis or urethral stenosis.

          -  Patient with an implant located less than 1 cm from the treatment zone (stent,
             catheter).

          -  Urogenital infection.

          -  Latex allergy

          -  Contraindication to MRI (pacemaker,metal prosthesis ...)

          -  Patient participated in another clinical study within 30 days.

          -  Illiterate patients

          -  Legally incapable patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Bladou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital,Urology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Bladou, MD</last_name>
    <phone>1-514-340-8222</phone>
    <phone_ext>5166</phone_ext>
    <email>fbladou@jgh.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques Corcos, MD</last_name>
    <phone>1-514-340-8222</phone>
    <phone_ext>5166</phone_ext>
    <email>jcorcos@jgh.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jewish General Hospital,Urology Department</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Bladou, MD</last_name>
      <phone>1-514-340-8222</phone>
      <phone_ext>5166</phone_ext>
      <email>fbladou@jgh.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Oleg Loutochin</last_name>
      <phone>1-514-340-8222</phone>
      <phone_ext>1627</phone_ext>
      <email>oloutochin@jgh.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Franck Bladou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurice Anidjar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques Corcos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr.Franck Bladou</investigator_full_name>
    <investigator_title>MD.  Professor of Oncology and Urology, McGill University</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>HIFU Hemi-ablation</keyword>
  <keyword>Prostate biopsies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
